T1	intervention 58 66	Olaparib
T3	eligibility 761 872	enrolled patients with a germline BRCAm and HER2-negative mBC who had received â‰¤2 lines of chemotherapy for mBC
T2	outcome-Measure 993 995	OS
T4	outcome-Measure 1000 1006	safety
T5	intervention-participants 1045 1048	205
T6	control 935 950	predeclared TPC
T7	control-participants 1090 1092	97
T8	outcome 1123 1132	median OS
T9	outcome 1288 1297	HR for OS
T10	outcome 1355 1381	prior chemotherapy for mBC
T11	outcome 1475 1490	receptor status
T12	outcome 1571 1585	prior platinum
T13	outcome 1631 1645	Adverse events
T14	outcome 1774 1807	rate of treatment discontinuation
